Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis.

Välimäki M, Nilsson CG, Roine R, Ylikorkala O

The Journal of clinical endocrinology and metabolism1 Dec 1989Cited by 24 (Europe PMC)

PMID2531153DOI10.1210/jcem-69-6-1097PepBankPUB-02531153

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, total HDL cholesterol increased slightly during nafarelin treatment.
In plain wordsIn patients with endometriosis, total HDL cholesterol increased slightly during nafarelin treatment.
Peptide
Nafarelin
Outcome
IncreaseTotal HDL cholesterol
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
On nafarelin treatment, serum total HDL and HDL2 cholesterol concentrations increased slightly, but total and low density lipoprotein (LDL) cholesterol levels were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115301
02HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, HDL2 cholesterol increased slightly during nafarelin treatment.
In plain wordsIn patients with endometriosis, HDL2 cholesterol increased slightly during nafarelin treatment.
Peptide
Nafarelin
Outcome
IncreaseHDL2 cholesterol
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
On nafarelin treatment, serum total HDL and HDL2 cholesterol concentrations increased slightly, but total and low density lipoprotein (LDL) cholesterol levels were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115302
03HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, total cholesterol remained unchanged during nafarelin treatment.
In plain wordsIn patients with endometriosis, total cholesterol remained unchanged during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeTotal cholesterol
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
On nafarelin treatment, serum total HDL and HDL2 cholesterol concentrations increased slightly, but total and low density lipoprotein (LDL) cholesterol levels were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115303
04HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, LDL cholesterol remained unchanged during nafarelin treatment.
In plain wordsIn patients with endometriosis, LDL cholesterol remained unchanged during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeLDL cholesterol
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
On nafarelin treatment, serum total HDL and HDL2 cholesterol concentrations increased slightly, but total and low density lipoprotein (LDL) cholesterol levels were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115304
05HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin had no effect on apoprotein A-I.
In plain wordsIn patients with endometriosis, apoprotein A-I did not change during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeApoprotein A-I
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
There was no effect on apoproteins-A-I and -A-II or on total and very low density lipoprotein (VLDL) triglyceride concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115305
06HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin had no effect on apoprotein A-II.
In plain wordsIn patients with endometriosis, apoprotein A-II did not change during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeApoprotein A-II
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
There was no effect on apoproteins-A-I and -A-II or on total and very low density lipoprotein (VLDL) triglyceride concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115306
07HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin had no effect on total triglycerides.
In plain wordsIn patients with endometriosis, total triglycerides did not change during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeTotal triglycerides
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
There was no effect on apoproteins-A-I and -A-II or on total and very low density lipoprotein (VLDL) triglyceride concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115307
08HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin had no effect on VLDL triglycerides.
In plain wordsIn patients with endometriosis, VLDL triglycerides did not change during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeVLDL triglycerides
Study
n = 12
Comparator
Pretreatment
Outcome group
Lipids · Metabolic and weight
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
There was no effect on apoproteins-A-I and -A-II or on total and very low density lipoprotein (VLDL) triglyceride concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115308
09HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, serum testosterone decreased during nafarelin treatment.
In plain wordsIn patients with endometriosis, testosterone decreased during nafarelin treatment.
Peptide
Nafarelin
Outcome
DecreaseSerum testosterone
Study
n = 12
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
The steep drop in the serum sex hormone-binding globulin level reflected the androgenic effect of danazol, whereas during nafarelin treatment, serum concentrations of testosterone and androstenedione were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115310
10HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, serum androstenedione decreased during nafarelin treatment.
In plain wordsIn patients with endometriosis, androstenedione decreased during nafarelin treatment.
Peptide
Nafarelin
Outcome
DecreaseSerum androstenedione
Study
n = 12
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
The steep drop in the serum sex hormone-binding globulin level reflected the androgenic effect of danazol, whereas during nafarelin treatment, serum concentrations of testosterone and androstenedione were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115311
11HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin and danazol produced hypoestrogenism of the same degree.
In plain wordsIn patients with endometriosis, nafarelin and danazol reduced estrogen to a similar degree.
Peptide
Nafarelin
Outcome
Direction not reportedHypoestrogenism
Study
n: not reported in source
Comparator
Danazol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms dailyAs given in this study (human).
Source sentences
Summary
Both treatments resulted in hypoestrogenism of the same degree.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of nafarelin (400 micrograms daily; 12 patients) and danazol (600 mg daily; 6 patients) on serum lipoproteins, high density lipoprotein (HDL) subfractions, and apoproteins-A-I and -A-II were studied.
Report a problemFND-0253115309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.